% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cabo:178057,
      author       = {M. Cabo and R. Offringa$^*$ and L. Zitvogel and G. Kroemer
                      and A. Muntasell and L. Galluzzi},
      title        = {{T}rial {W}atch: {I}mmunostimulatory monoclonal antibodies
                      for oncological indications.},
      journal      = {OncoImmunology},
      volume       = {6},
      number       = {12},
      issn         = {2162-4011},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Franics},
      reportid     = {DKFZ-2021-03066},
      pages        = {e1371896 -},
      year         = {2017},
      note         = {POF Topic: 317},
      abstract     = {The goal of cancer immunotherapy is to establish new or
                      boost pre-existing anticancer immune responses that
                      eradicate malignant cells while generating immunological
                      memory to prevent disease relapse. Over the past few years,
                      immunomodulatory monoclonal antibodies (mAbs) that block
                      co-inhibitory receptors on immune effectors cells - such as
                      cytotoxic T lymphocyte-associated protein 4 (CTLA4),
                      programmed cell death 1 (PDCD1, best known as PD-1) - or
                      their ligands - such as CD274 (best known as PD-L1) - have
                      proven very successful in this sense. As a consequence, many
                      of such immune checkpoint blockers (ICBs) have already
                      entered the clinical practice for various oncological
                      indications. Considerable attention is currently being
                      attracted by a second group of immunomodulatory mAbs, which
                      are conceived to activate co-stimulatory receptors on immune
                      effector cells. Here, we discuss the mechanisms of action of
                      these immunostimulatory mAbs and summarize recent progress
                      in their preclinical and clinical development.},
      subtyp        = {Review Article},
      keywords     = {CD137 (Other) / CD40 (Other) / GITR (Other) / ICOS (Other)
                      / OX40 (Other) / PD-1 (Other)},
      cin          = {G180},
      ddc          = {610},
      cid          = {I:(DE-He78)G180-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29209572},
      pmc          = {pmc:PMC5706611},
      doi          = {10.1080/2162402X.2017.1371896},
      url          = {https://inrepo02.dkfz.de/record/178057},
}